FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3195678305> ?p ?o ?g. }

• W3195678305 endingPage "S226" @default.
• W3195678305 startingPage "S226" @default.
• W3195678305 abstract "The APACT trial evaluated the safety and efficacy of adjuvant nab -P + Gem vs Gem alone in patients with resected PC. Between April 2014 and April 2016, 866 patients were randomized. As previously reported, APACT did not meet the primary endpoint of independently assessed disease-free survival (DFS); however, the prespecified sensitivity analysis for median investigator-assessed DFS was 16.6 months with nab -P + Gem and 13.7 months with Gem (HR, 0.82; 95% CI, 0.694–0.965; nominal P=0.0168). The overall survival (OS; secondary endpoint) at the time of the primary analysis trended in favor of nab -P + Gem: median 40.5 vs 36.2 months (427 events; 68% mature; HR, 0.82; 95% CI, 0.680–0.996; nominal P=0.045). The post hoc updated follow-up survival analysis outcomes were consistent with those observed in the primary analysis of nab -P + Gem vs Gem: median 41.8 vs 37.7 months (511 events; 81% mature; HR, 0.82; 95% CI, 0.687–0.973; nominal P=0.0232). Safety outcomes as previously presented were consistent with those reported in the treated population for the entire trial. Here, we present updated 5-year OS in the intent-to-treat population. Treatment-naive patients with histologically confirmed pancreatic adenocarcinoma, macroscopic complete resection (R0 or R1), Eastern Cooperative Oncology Group performance status 0 or 1, and carbohydrate antigen 19-9 levels < 100 U/mL were eligible. Stratification factors were resection status (R0 vs R1), lymph node status (positive vs negative) and region (North America, Europe, and Australia vs. Asia Pacific). Treatment was initiated ≤12 weeks postsurgery. Patients received nab-P 125 mg/m2 + Gem 1000 mg/m2 or Gem 1000 mg/m2 on days 1, 8, and 15 of six 28-day cycles. The primary endpoint was DFS by independent review. Secondary endpoints were OS and safety. Treatment-naive patients with histologically confirmed pancreatic adenocarcinoma, macroscopic complete resection (R0 or R1), Eastern Cooperative Oncology Group performance status of 0 or 1, and carbohydrate antigen 19-9 levels nab -P 125 mg/m2 + Gem 1000 mg/m2 or Gem 1000 mg/m2 on days 1, 8, and 15 of six 28-day cycles. The primary endpoint was DFS by independent review. Secondary endpoints were OS and safety. As of the data cutoff date (9 April 2021), all patients had been followed up for ≥5 years or discontinued from the study. The median follow-up time for OS was 63.2 months. In the intent-to-treat population, 268 and 287 events occurred in the nab -P + Gem and Gem arms, respectively (88% mature). The median OS in the nab -P + Gem arm was 41.8 months compared with 37.7 months in the Gem arm (HR, 0.80; 95% CI, 0.678–0.947; nominal P=0.0091). Five-year OS rates were 38% with nab -P + Gem and 31% with Gem. Patterns of OS in the prespecified subgroups were generally consistent with observations from the intent-to-treat population: R0 (HR, 0.85; 95% CI, 0.698–1.034); R1 (HR, 0.73; 95% CI, 0.534–1.003); LN+ (HR, 0.77; 95% CI, 0.636–0.922); LN− (HR, 0.97; 95% CI, 0.667–1.415). The 5-year OS outcomes in the APACT trial were consistent with those observed in both the primary analysis and the prior post hoc updated analysis for nab -P + Gem vs Gem alone. Although APACT did not meet its primary endpoint of independently assessed DFS in the primary analysis, these OS data suggest improved outcomes with nab -P + Gem." @default.
• W3195678305 created "2021-08-30" @default.
• W3195678305 creator A5003425445 @default.
• W3195678305 creator A5011795261 @default.
• W3195678305 creator A5015509025 @default.
• W3195678305 creator A5015610217 @default.
• W3195678305 creator A5015800200 @default.
• W3195678305 creator A5018257387 @default.
• W3195678305 creator A5020108110 @default.
• W3195678305 creator A5024180743 @default.
• W3195678305 creator A5039492614 @default.
• W3195678305 creator A5044174993 @default.
• W3195678305 creator A5057350576 @default.
• W3195678305 creator A5060129800 @default.
• W3195678305 creator A5067787981 @default.
• W3195678305 creator A5070309355 @default.
• W3195678305 creator A5072641295 @default.
• W3195678305 creator A5073873438 @default.
• W3195678305 creator A5076438320 @default.
• W3195678305 creator A5080423970 @default.
• W3195678305 creator A5084084260 @default.
• W3195678305 creator A5086605611 @default.
• W3195678305 creator A5089677089 @default.
• W3195678305 creator A5090645179 @default.
• W3195678305 date "2021-07-01" @default.
• W3195678305 modified "2023-10-17" @default.
• W3195678305 title "LBA-1 Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): Updated 5-year overall survival" @default.
• W3195678305 doi "https://doi.org/10.1016/j.annonc.2021.06.009" @default.
• W3195678305 hasPublicationYear "2021" @default.
• W3195678305 type Work @default.
• W3195678305 sameAs 3195678305 @default.
• W3195678305 citedByCount "19" @default.
• W3195678305 countsByYear W31956783052021 @default.
• W3195678305 countsByYear W31956783052022 @default.
• W3195678305 countsByYear W31956783052023 @default.
• W3195678305 crossrefType "journal-article" @default.
• W3195678305 hasAuthorship W3195678305A5003425445 @default.
• W3195678305 hasAuthorship W3195678305A5011795261 @default.
• W3195678305 hasAuthorship W3195678305A5015509025 @default.
• W3195678305 hasAuthorship W3195678305A5015610217 @default.
• W3195678305 hasAuthorship W3195678305A5015800200 @default.
• W3195678305 hasAuthorship W3195678305A5018257387 @default.
• W3195678305 hasAuthorship W3195678305A5020108110 @default.
• W3195678305 hasAuthorship W3195678305A5024180743 @default.
• W3195678305 hasAuthorship W3195678305A5039492614 @default.
• W3195678305 hasAuthorship W3195678305A5044174993 @default.
• W3195678305 hasAuthorship W3195678305A5057350576 @default.
• W3195678305 hasAuthorship W3195678305A5060129800 @default.
• W3195678305 hasAuthorship W3195678305A5067787981 @default.
• W3195678305 hasAuthorship W3195678305A5070309355 @default.
• W3195678305 hasAuthorship W3195678305A5072641295 @default.
• W3195678305 hasAuthorship W3195678305A5073873438 @default.
• W3195678305 hasAuthorship W3195678305A5076438320 @default.
• W3195678305 hasAuthorship W3195678305A5080423970 @default.
• W3195678305 hasAuthorship W3195678305A5084084260 @default.
• W3195678305 hasAuthorship W3195678305A5086605611 @default.
• W3195678305 hasAuthorship W3195678305A5089677089 @default.
• W3195678305 hasAuthorship W3195678305A5090645179 @default.
• W3195678305 hasBestOaLocation W31956783051 @default.
• W3195678305 hasConcept C121608353 @default.
• W3195678305 hasConcept C126322002 @default.
• W3195678305 hasConcept C141071460 @default.
• W3195678305 hasConcept C143998085 @default.
• W3195678305 hasConcept C168563851 @default.
• W3195678305 hasConcept C203092338 @default.
• W3195678305 hasConcept C2777863537 @default.
• W3195678305 hasConcept C2780210213 @default.
• W3195678305 hasConcept C2780258809 @default.
• W3195678305 hasConcept C2780849966 @default.
• W3195678305 hasConcept C2908647359 @default.
• W3195678305 hasConcept C2910430875 @default.
• W3195678305 hasConcept C71924100 @default.
• W3195678305 hasConcept C90924648 @default.
• W3195678305 hasConcept C99454951 @default.
• W3195678305 hasConceptScore W3195678305C121608353 @default.
• W3195678305 hasConceptScore W3195678305C126322002 @default.
• W3195678305 hasConceptScore W3195678305C141071460 @default.
• W3195678305 hasConceptScore W3195678305C143998085 @default.
• W3195678305 hasConceptScore W3195678305C168563851 @default.
• W3195678305 hasConceptScore W3195678305C203092338 @default.
• W3195678305 hasConceptScore W3195678305C2777863537 @default.
• W3195678305 hasConceptScore W3195678305C2780210213 @default.
• W3195678305 hasConceptScore W3195678305C2780258809 @default.
• W3195678305 hasConceptScore W3195678305C2780849966 @default.
• W3195678305 hasConceptScore W3195678305C2908647359 @default.
• W3195678305 hasConceptScore W3195678305C2910430875 @default.
• W3195678305 hasConceptScore W3195678305C71924100 @default.
• W3195678305 hasConceptScore W3195678305C90924648 @default.
• W3195678305 hasConceptScore W3195678305C99454951 @default.
• W3195678305 hasLocation W31956783051 @default.
• W3195678305 hasOpenAccess W3195678305 @default.
• W3195678305 hasPrimaryLocation W31956783051 @default.
• W3195678305 hasRelatedWork W2052188532 @default.
• W3195678305 hasRelatedWork W2094153719 @default.
• W3195678305 hasRelatedWork W2126322332 @default.
• W3195678305 hasRelatedWork W2596055884 @default.
• W3195678305 hasRelatedWork W2885862304 @default.
• W3195678305 hasRelatedWork W3031244932 @default.

• next